IL-33 (human) (rec.) (His)
510 CHF CHF 510.00
CHI-HR-20033-C02020 µgCHF 510.00
CHI-HR-20033-C05050 µgCHF 770.00
|Synonyms||Interleukin-33; IL-1F11; NF-HEV|
|Sequence||Human IL-33 (aa 112-270) is fused at the N-terminus to a His-tag.|
|Endotoxin Content||<1EU/μg protein (LAL test; Lonza).|
|Reconstitution||Reconstituted in sterile H2O not less than 100μg/ml, which can then be further diluted in other aqueous solutions.|
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS (pH 7.4).|
|Other Product Data||NCBI reference AAH47085.1: IL-33 (human)|
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.